Have You or Your Teen* Been Diagnosed with Peanut Allergy?
You may be eligible
for a new research study.
IgGenix ACCELERATE Peanut Study
Now Recruiting!
If you or your teen* has been diagnosed with severe peanut allergy, you may be eligible to take part in a new study exploring whether an investigational medicine called IGNX001 can help treat peanut allergy in teens and adults.
Overview
The phase 1, randomised, double-blind study will evaluate the safety and tolerability of an injectable, allergen-specific antibodies that targets peanut protein.
The study will help understand if IGNX001 can be used to help ease allergic reactions that might happen after accidental peanut exposure. It will monitor the safety of IGNX001, track how participants respond to it, and explore whether participants improve their tolerance to peanut protein exposure after receiving IGNX001.
The study is recruiting participants at Fiona Stanley Hospital (Western Australia), St Vincent’s Hospital (New South Wales), The Royal Melbourne Hospital and Monash Health (Victoria).
What’s involved in the study
The study runs for up to six months, and involves:
-
Regular visits to your study centre
-
Receiving up to four injections
-
Undertaking a series of tests and assessments to monitor your health during the study, including your medical history, prior and current medications, physical exams, blood and urine samples, electrocardiograms (ECG), skin prick tests and peanut oral food challenges.
For more information, see ClinicalTrials.gov.
Who can take part?
To pre-qualify for this study, you or your teen must:
-
Be 15 to 55 years old*
-
Have a history of severe peanut allergy, including having experienced a serious allergic reaction to peanut in the past 15 years
-
Be willing to avoid peanuts and other allergy inducing foods during the study.
-
Have been prescribed an adrenaline autoinjector (EpiPen or Anapen)
You or your teen cannot take part if you have:
-
A history of severe or uncontrolled asthma within the past six months
-
Any clinically significant liver, kidney, cardiac or mast cell disease or uncontrolled chronic disease
-
Received food allergen immunotherapy treatment or participated in a similar study in the past 12 months
* Only Fiona Stanely Hospital and Monash Health are recruiting teens (ages 15-18)
Interested? Reach out to your local study site:
Fiona Stanley Hospital
11 Robin Warren Drive
Murdoch WA 6150, Australia
Recruiting ages 15-55
St Vincent’s Sydney
390 Victoria Street
Darlinghurst NSW 2010, Australia
Recruiting ages 18-55
Monash Health
246 Clayton Road
Clayton VIC 3168, Australia
Recruiting ages 15-55
Royal Melbourne Hospital
300 Grattan Street
Parkville, VIC 3050, Australia
Recruiting ages 18-55
This research has been approved by the South Metropolitan Health Service HREC (for all sites outside of NSW) & Bellberry HREC (NSW).
© 2024 IgGenix Australia Pty Ltd. All rights reserved.